Lidocaine Grindeks: Uses, Dosage & Side Effects

What Is Lidocaine Grindeks and What Is It Used For?

Lidocaine Grindeks contains the active substance lidocaine hydrochloride, an amide-type local anesthetic that was first synthesized in 1943 by Nils Löfgren and Bengt Lundqvist at the University of Stockholm. It was introduced into clinical practice in 1948 and quickly became the gold standard among local anesthetics due to its rapid onset of action, predictable duration, excellent tissue penetration, and favorable safety profile. Today, lidocaine remains one of the most frequently used local anesthetics in medicine and dentistry across the globe, and it is recognized by the World Health Organization (WHO) as an essential medicine.

Lidocaine exerts its anesthetic effect by reversibly blocking voltage-gated sodium channels in the nerve cell membrane. Under normal physiological conditions, these sodium channels open in response to a stimulus, allowing sodium ions to flow into the nerve cell, which generates an action potential that propagates along the nerve fiber to transmit pain signals to the brain. When lidocaine binds to the intracellular portion of these sodium channels in their inactivated state, it prevents the channels from opening, thereby blocking the initiation and conduction of nerve impulses. This results in a temporary loss of sensation (numbness) in the area supplied by the affected nerves.

The selectivity of lidocaine's nerve blockade follows a well-established pattern related to nerve fiber diameter and myelination. Small-diameter, unmyelinated C fibers (which transmit pain and temperature) are blocked first, followed by small myelinated A-delta fibers (sharp pain, temperature), then larger myelinated fibers responsible for touch, proprioception, and motor function. This differential blockade means that pain sensation is typically lost before touch, and motor function is the last to be affected, which is clinically advantageous as it allows pain-free procedures while the patient may retain some sensation of pressure or movement.

Lidocaine Grindeks solution for injection (20 mg/ml, corresponding to 2% concentration) is indicated for the following types of regional anesthesia:

• Infiltration anesthesia: Direct injection into the tissue to numb a localized area. Commonly used for wound suturing, minor skin surgery, biopsies, and dental procedures such as fillings and extractions.
• Peripheral nerve blocks: Injection near specific peripheral nerves or nerve plexuses to anesthetize larger regions of the body. Used for upper and lower extremity surgery, dental nerve blocks (inferior alveolar, mental, infraorbital), intercostal blocks, and various other surgical procedures.
• Epidural anesthesia: Injection into the epidural space of the spinal column. Used for surgical anesthesia of the lower body, labor and delivery analgesia, and postoperative pain management. Lidocaine 2% provides rapid onset epidural anesthesia with intermediate duration.
• Intravenous regional anesthesia (Bier block): A specialized technique where lidocaine is injected intravenously into a limb isolated by a tourniquet. Used for short surgical procedures on the forearm, hand, or foot.

The pharmacokinetic properties of lidocaine contribute to its clinical utility. After local injection, lidocaine has a rapid onset of action, typically within 1 to 5 minutes for infiltration anesthesia and 5 to 15 minutes for peripheral nerve blocks. The duration of anesthesia depends on several factors, including the dose, concentration, injection site, vascularity of the tissue, and whether a vasoconstrictor is used. Without epinephrine, infiltration anesthesia with lidocaine 2% typically lasts 1 to 2 hours. When combined with epinephrine (adrenaline), which causes local vasoconstriction and slows absorption, the duration can be extended to 2 to 3 hours, and the maximum safe dose is also increased.

Lidocaine is absorbed from the injection site at a rate determined by the vascularity of the tissue and the presence of vasoconstrictors. After absorption into the systemic circulation, it is distributed throughout the body with a volume of distribution of approximately 1.5 L/kg. Lidocaine is approximately 60–80% bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG). It crosses both the blood-brain barrier and the placenta. Hepatic metabolism is the primary route of elimination, with lidocaine being metabolized by the cytochrome P450 enzymes CYP1A2 and CYP3A4 to two active metabolites: monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Approximately 90% of a dose is excreted renally as metabolites, with less than 10% excreted unchanged. The elimination half-life of lidocaine is approximately 1.5 to 2 hours in healthy adults, but may be significantly prolonged in patients with liver disease, heart failure, or those receiving medications that inhibit its hepatic metabolism.

What Should You Know Before Taking Lidocaine Grindeks?

Contraindications

Lidocaine Grindeks must not be used in the following situations:

• Hypersensitivity: Known allergy to lidocaine, other amide-type local anesthetics (such as bupivacaine, mepivacaine, prilocaine, ropivacaine, or articaine), or any of the excipients in the formulation. True allergy to amide-type local anesthetics is extremely rare (less than 1% of all reported adverse reactions to local anesthetics are truly allergic in nature), but when it occurs, it can be severe. Patients with a confirmed allergy to one amide-type local anesthetic should be assumed to be at risk of cross-reactivity with other amide-type agents.
• Severe sinoatrial, atrioventricular, or intraventricular heart block: Unless a pacemaker is in place. Lidocaine has Class Ib antiarrhythmic properties and can suppress cardiac conduction, potentially worsening these conditions.
• Severe decompensated heart failure: Patients with severely compromised myocardial function may be more susceptible to the cardiovascular depressant effects of lidocaine.
• Hypovolemia: In patients with significantly reduced blood volume, the relative concentration of lidocaine absorbed systemically may be higher, increasing the risk of toxicity.
• Administration route restrictions: Lidocaine Grindeks solution for injection (without preservatives when indicated for epidural use) must not be injected intravenously for regional anesthetic purposes without appropriate tourniquet control. The 2% concentration should not be used for spinal (intrathecal) anesthesia, as specific hyperbaric solutions are required for that route.

Warnings and Precautions

Before receiving Lidocaine Grindeks, your healthcare provider should be informed about the following conditions and circumstances:

• Liver disease: Lidocaine is primarily metabolized in the liver. Patients with hepatic impairment (including cirrhosis, hepatitis, or reduced liver blood flow) may have significantly reduced clearance of lidocaine, leading to higher plasma concentrations and increased risk of systemic toxicity. Dose reductions and careful monitoring are required.
• Heart failure: Patients with congestive heart failure may have reduced hepatic blood flow and reduced protein binding, both of which can increase free (active) lidocaine concentrations. Additionally, the myocardial depressant effects of lidocaine may be more pronounced in patients with pre-existing cardiac dysfunction.
• Cardiac conduction disorders: Lidocaine has Class Ib antiarrhythmic properties. While it is generally well tolerated at anesthetic doses, patients with pre-existing conduction abnormalities (partial heart block, bundle branch block, or bradycardia) should be monitored closely, as lidocaine may further slow conduction.
• Epilepsy: Lidocaine can lower the seizure threshold. Patients with a history of epilepsy or other seizure disorders may be at increased risk of seizure activity, particularly if plasma concentrations exceed the therapeutic range. Doses should be carefully calculated and not exceeded.
• Porphyria: Lidocaine has been associated with precipitation of acute porphyria attacks in susceptible individuals. Patients with known or suspected porphyria should discuss the risks and alternatives with their physician.
• Elderly and debilitated patients: These patients may require reduced doses due to age-related reductions in hepatic blood flow, lean body mass, and serum protein levels. They are also more susceptible to the cardiovascular effects of lidocaine.
• Acutely ill patients: Patients who are acutely ill, febrile, or in a generally weakened condition may be more sensitive to the systemic effects of local anesthetics and may require lower doses.
• Injection site considerations: Highly vascular areas (such as the head and neck region) result in faster absorption and higher peak plasma concentrations. The maximum dose should be adjusted accordingly, and aspiration before injection is essential to avoid accidental intravascular injection.

Pregnancy and Breastfeeding

Lidocaine crosses the placental barrier and can reach the fetus. However, lidocaine has been used extensively in obstetric practice for decades and is generally considered acceptable for use during pregnancy when clinically indicated, provided the lowest effective dose is used and the potential benefits outweigh the potential risks to the fetus.

Lidocaine is commonly used for epidural anesthesia and analgesia during labor and delivery. This application has a well-established safety record when performed by experienced anesthesiologists with appropriate monitoring. However, paracervical block with lidocaine should be used with caution or avoided during labor, as this technique has been associated with fetal bradycardia due to high fetal plasma concentrations of the drug.

Animal reproductive studies have not demonstrated teratogenic effects. However, high doses or prolonged exposure in late pregnancy may cause neonatal depression (reduced muscle tone, respiratory depression). If lidocaine is used near term, the newborn should be monitored for any signs of toxicity.

Lidocaine is excreted in breast milk in small amounts. The amount transferred to the nursing infant following a standard anesthetic dose is considered clinically insignificant, and breastfeeding can generally be continued. The ratio of lidocaine concentration in breast milk to plasma is approximately 0.4. If you are breastfeeding, inform your healthcare provider so that the dosing can be optimized.

Children and Adolescents

Lidocaine can be used in pediatric patients, but the dose must be carefully calculated based on the child's body weight. Children, particularly neonates and young infants, have immature hepatic enzyme systems and reduced protein binding, which can result in higher free drug concentrations and increased sensitivity to the systemic effects of lidocaine. The maximum recommended dose in children should not exceed 4.5 mg/kg without epinephrine or 7 mg/kg with epinephrine, and many guidelines recommend using even lower doses in young children. Practitioners experienced in pediatric anesthesia should administer the drug with appropriate monitoring equipment available.

How Does Lidocaine Grindeks Interact with Other Drugs?

Lidocaine is metabolized primarily by the hepatic cytochrome P450 enzymes CYP1A2 and CYP3A4. As a result, medications that affect the activity of these enzymes or that alter hepatic blood flow can significantly influence lidocaine plasma concentrations and, consequently, the risk of systemic toxicity. Additionally, pharmacodynamic interactions can occur with drugs that have similar effects on the nervous system or cardiovascular system.

The following table summarizes the most clinically significant drug interactions with lidocaine:

Particular caution is warranted when lidocaine is used in patients receiving multiple medications that can reduce its hepatic clearance. The combination of a beta-blocker with a CYP1A2 inhibitor, for example, can produce a marked and clinically significant increase in lidocaine plasma levels. In such patients, the dose of lidocaine should be reduced and the patient monitored for early signs of systemic toxicity, including perioral numbness, metallic taste, lightheadedness, and tinnitus.

When lidocaine is used in combination with epinephrine (adrenaline) as a vasoconstrictor, additional drug interactions must be considered. Epinephrine can interact with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and non-selective beta-blockers, potentially causing hypertensive episodes or cardiovascular complications. Patients receiving these medications should inform their healthcare provider before any procedure involving lidocaine with epinephrine.

What Is the Correct Dosage of Lidocaine Grindeks?

Lidocaine Grindeks should always be administered by or under the direct supervision of a healthcare professional experienced in regional anesthesia techniques. The dose, concentration, and volume to be used depend on the specific anesthetic technique, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth and duration of anesthesia required, individual patient tolerance, and the physical condition of the patient. The lowest dose and concentration that produces the desired result should always be used.

Adults

The maximum recommended single dose of lidocaine for adults is 4.5 mg/kg body weight without epinephrine (adrenaline) and 7 mg/kg body weight with epinephrine, up to absolute maximums of approximately 300 mg and 500 mg respectively. These maximum doses should not be exceeded within a 2-hour period. For a 70 kg adult, this translates to a maximum of approximately 315 mg (15.75 ml of 2% solution) without epinephrine, or 490 mg (24.5 ml of 2% solution) with epinephrine.

When epinephrine is added to lidocaine (typically at a concentration of 1:200,000, or 5 micrograms/ml), it produces local vasoconstriction at the injection site. This slows the rate of vascular absorption, which serves two purposes: it extends the duration of anesthesia by keeping lidocaine at the nerve site longer, and it reduces peak plasma concentrations, thereby improving the safety margin and allowing higher doses. However, epinephrine-containing solutions should not be used in areas supplied by end arteries (such as fingers, toes, the tip of the nose, ears, or the penis), as vasoconstriction in these areas could cause ischemic tissue damage.

Children

In pediatric patients, the dose must be carefully calculated based on the child's body weight. The maximum dose should not exceed 4.5 mg/kg without epinephrine or 7 mg/kg with epinephrine. In neonates and young infants (under 6 months of age), even lower doses may be appropriate due to immature hepatic metabolism and reduced protein binding. Children should be monitored for early signs of systemic toxicity throughout the procedure.

For dental procedures in children, the commonly used dose is 1–2 ml of 2% lidocaine with epinephrine per injection site, with the total dose carefully calculated not to exceed the weight-based maximum. A helpful conversion: each milliliter of Lidocaine Grindeks 20 mg/ml contains 20 mg of lidocaine.

Elderly Patients

Elderly patients generally require reduced doses of lidocaine. Age-related reductions in hepatic blood flow, hepatic enzyme activity, and lean body mass mean that the same milligram dose can produce higher and more prolonged plasma concentrations compared to younger adults. Additionally, elderly patients may have increased sensitivity to the cardiovascular and central nervous system effects of lidocaine. Dose reductions of 20–30% from standard adult doses are often recommended, and the injection should be performed slowly with frequent aspiration.

Missed Dose

Lidocaine Grindeks is administered by healthcare professionals during specific medical procedures and is not a medication taken on a regular schedule. Therefore, the concept of a missed dose does not apply. Each dose is determined and administered at the time of the procedure based on clinical judgment.

Overdose

Overdose with lidocaine, whether from accidental intravascular injection, excessive dosing, or rapid absorption from highly vascular tissue, can result in local anesthetic systemic toxicity (LAST). This is a medical emergency that requires immediate recognition and treatment.

The progression of LAST symptoms typically follows a predictable pattern based on rising plasma lidocaine concentrations:

• Mild toxicity (plasma concentration 5–10 µg/ml): Circumoral numbness, metallic taste, tinnitus (ringing in the ears), lightheadedness, dizziness, visual disturbances, drowsiness, and restlessness.
• Moderate toxicity (plasma concentration 10–15 µg/ml): Slurred speech, nystagmus (involuntary eye movements), muscle twitching, tremors, nausea, and vomiting.
• Severe toxicity (plasma concentration >15 µg/ml): Generalized seizures, loss of consciousness, respiratory arrest, cardiovascular depression (hypotension, bradycardia), and in extreme cases, cardiac arrest.

Treatment of LAST includes immediate cessation of lidocaine injection, airway management with supplemental oxygen, seizure control with benzodiazepines (midazolam or diazepam), and cardiovascular support. The cornerstone of treatment for severe LAST is intravenous lipid emulsion therapy (ILE), typically Intralipid 20%, which acts as a “lipid sink” to bind free lidocaine and reduce its plasma concentration. Current guidelines recommend an initial bolus of Intralipid 20% at 1.5 ml/kg followed by an infusion of 0.25 ml/kg/min for at least 10 minutes beyond cardiovascular stability. All facilities where local anesthetics are administered should have lipid emulsion immediately available.

What Are the Side Effects of Lidocaine Grindeks?

Like all medicines, Lidocaine Grindeks can cause side effects, although not everyone will experience them. The majority of adverse effects associated with lidocaine are dose-related and result from the pharmacological effects of the drug on the nervous and cardiovascular systems. Most are temporary and resolve completely as the drug is metabolized and eliminated from the body. True allergic reactions to amide-type local anesthetics are extremely rare.

The side effects of lidocaine can be categorized as either local effects at the injection site or systemic effects resulting from absorption of the drug into the general circulation. Systemic effects are more likely to occur with higher doses, rapid injection, accidental intravascular administration, or in patients with conditions that reduce lidocaine clearance (such as liver disease or heart failure).

Systemic toxicity from lidocaine typically follows a dose-dependent progression affecting the central nervous system (CNS) before the cardiovascular system (CVS). At lower toxic plasma concentrations, CNS excitatory symptoms predominate (tinnitus, metallic taste, perioral numbness, restlessness, muscle twitching). As plasma concentrations increase further, CNS depression occurs (drowsiness, slurred speech, loss of consciousness, seizures, respiratory arrest). Cardiovascular toxicity occurs at even higher concentrations and includes hypotension, bradycardia, conduction disturbances, and cardiac arrest. The ratio of the dose causing cardiovascular collapse to the dose causing seizures (the CC/CNS ratio) is higher for lidocaine than for more cardiotoxic agents such as bupivacaine, which contributes to lidocaine's relatively wide safety margin.

Post-dural puncture headache (PDPH) is a specific complication that can occur after epidural anesthesia if the dura mater is accidentally punctured (known as a “wet tap”). This headache is characteristically positional, worsening when upright and improving when lying flat. It is caused by leakage of cerebrospinal fluid through the dural puncture site. Conservative management includes bed rest, hydration, and analgesics. If severe, an epidural blood patch may be required.

True allergic reactions to lidocaine and other amide-type local anesthetics are exceedingly rare. Many reported “allergic reactions” to local anesthetics are actually vasovagal episodes (fainting), anxiety reactions, or responses to co-administered epinephrine. When genuine allergy to an amide-type local anesthetic is suspected, formal allergy testing (skin prick and intradermal testing) should be performed by an allergist before future procedures.

How Should You Store Lidocaine Grindeks?

Proper storage of Lidocaine Grindeks is essential to maintain the quality, safety, and efficacy of the medication. As a sterile solution intended for injection, any compromise in storage conditions could affect the sterility, chemical stability, or physical integrity of the product.

• Temperature: Store at a temperature not exceeding 25 °C (77 °F). Protect from excessive heat. Do not store near radiators, heating equipment, or in direct sunlight.
• Do not freeze: Freezing can damage the container and may affect the stability of the solution. If the product has been accidentally frozen, do not use it.
• Light protection: Keep the ampoules in the original outer carton to protect from light. Prolonged exposure to light may cause degradation of the active ingredient.
• Keep out of reach of children: Store in a secure area inaccessible to children and unauthorized persons.
• Expiration date: Do not use Lidocaine Grindeks after the expiration date printed on the ampoule label and outer carton. The expiration date refers to the last day of that month.
• Single use: Each ampoule is intended for single use only. Any remaining solution after use should be discarded in accordance with local requirements. Do not re-sterilize or reuse opened ampoules.
• Visual inspection: Before each use, healthcare professionals should visually inspect the solution. The solution should be clear and colorless. Do not use if the solution is cloudy, discolored, contains particles, or if the ampoule is damaged.

In healthcare facilities, Lidocaine Grindeks should be stored in a dedicated medication storage area with controlled temperature and access. Inventory management should follow the first-in, first-out (FIFO) principle to ensure that products with the earliest expiration dates are used first. Regular stock checks should be performed to remove expired or damaged units.

What Does Lidocaine Grindeks Contain?

Understanding the composition of Lidocaine Grindeks is important for healthcare professionals and patients, particularly those with known allergies or sensitivities to specific pharmaceutical ingredients. Below is a detailed breakdown of the product's composition.

Active Ingredient

The active substance is lidocaine hydrochloride (also known as lignocaine hydrochloride), an amide-type local anesthetic. Each milliliter of solution contains 20 mg of lidocaine hydrochloride, corresponding to a 2% (w/v) concentration. Lidocaine hydrochloride is the water-soluble salt form of the base lidocaine, which enables it to be formulated as an aqueous solution for injection. The molecular formula is C₁₄H₂₂N₂O · HCl · H₂O, with a molecular weight of 288.8 g/mol.

Inactive Ingredients (Excipients)

Appearance and Pack Sizes

Lidocaine Grindeks is supplied as a clear, colorless solution for injection in glass ampoules. Each ampoule contains 2 ml of solution (corresponding to 40 mg of lidocaine hydrochloride). The ampoules are packaged in cartons containing 10 ampoules. Not all pack sizes may be available in every country.

Marketing Authorization Holder and Manufacturer

Lidocaine Grindeks is manufactured and marketed by AS Grindeks, a pharmaceutical company headquartered in Riga, Latvia. AS Grindeks is one of the leading pharmaceutical companies in the Baltic region, with a manufacturing portfolio that includes a wide range of essential medicines. The company operates in compliance with European Good Manufacturing Practice (GMP) standards, and its products are distributed in multiple countries throughout Europe and beyond.

Lidocaine preparations are available from numerous manufacturers worldwide under various brand names (including Xylocaine by AstraZeneca, which was the original branded formulation). Lidocaine Grindeks is a generic formulation that is bioequivalent to the reference product and meets the same quality, safety, and efficacy standards as the original branded version.